ID: ALA5281587

Max Phase: Preclinical

Molecular Formula: C10H9ClN4

Molecular Weight: 220.66

Associated Items:

Representations

Canonical SMILES:  Nc1ccc(-c2cnc(Cl)c(N)c2)cn1

Standard InChI:  InChI=1S/C10H9ClN4/c11-10-8(12)3-7(5-15-10)6-1-2-9(13)14-4-6/h1-5H,12H2,(H2,13,14)

Standard InChI Key:  FHARCAKMRAVLEB-UHFFFAOYSA-N

Associated Targets(Human)

PI3-kinase p110-delta subunit 6699 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 220.66Molecular Weight (Monoisotopic): 220.0516AlogP: 1.96#Rotatable Bonds: 1
Polar Surface Area: 77.82Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 6.24CX LogP: 0.95CX LogD: 0.92
Aromatic Rings: 2Heavy Atoms: 15QED Weighted: 0.72Np Likeness Score: -0.30

References

1. Yang C, Gong Y, Gao Y, Deng M, Liu X, Yang Y, Ling Y, Jia Y, Zhou Y..  (2023)  Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3Kδ inhibitors for hematological cancer.,  82  [PMID:36706844] [10.1016/j.bmcl.2023.129152]

Source